There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Castle Biosciences (CSTL – Research Report) and AxoGen (AXGN – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Castle Biosciences (CSTL)
In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Castle Biosciences, with a price target of $35.00. The company’s shares closed last Tuesday at $16.32.
According to TipRanks.com, Flaten is a 1-star analyst with an average return of
Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $35.83, representing an 114.3% upside. In a report issued on July 15, TR | OpenAI – 4o also upgraded the stock to Buy with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
AxoGen (AXGN)
Lake Street analyst Frank Takkinen reiterated a Buy rating on AxoGen today and set a price target of $30.00. The company’s shares closed last Tuesday at $12.54.
According to TipRanks.com, Takkinen is a 1-star analyst with an average return of
Currently, the analyst consensus on AxoGen is a Strong Buy with an average price target of $24.00.
Read More on CSTL:
- Castle Biosciences announces DecisionDx-Melanoma test granted BD designation
- Castle Biosciences’ Strategic Partnership with SciBase: A Low-Risk Growth Opportunity in Atopic Dermatitis Testing
- Castle Biosciences enters collaboration, license agreement with SciBase
- Castle Biosciences management to meet virtually with Lake Street
- Castle Biosciences management to meet with KeyBanc